Medical Device Directive (MDD 93/42/EEC) is a 1993 European Union directive that sets the essential requirements, classification rules, and CE marking process for most medical devices sold in the EU. It has been repealed and replaced by EU MDR 2017/745, though transitional provisions still let some legacy devices remain on the market through 2027 or 2028.
What is the Medical Device Directive (MDD 93/42/EEC)?
Council Directive 93/42/EEC, adopted on June 14, 1993, was one of three original EU medical device directives, alongside the Active Implantable Medical Devices Directive (AIMDD 90/385/EEC) and the In Vitro Diagnostic Directive (IVDD 98/79/EC). It defined what counted as a medical device, laid out the essential requirements a device had to meet in Annex I, and set the classification and conformity assessment routes that determined how a manufacturer could earn CE marking.
For nearly three decades, MDD 93/42/EEC was the gateway to the EU and EEA market. A device that met its requirements and carried a valid Declaration of Conformity could move freely across member states without separate national approvals. That changed on May 26, 2021, when the EU Medical Device Regulation (MDR) 2017/745 became fully applicable, and the MDD was repealed for new market entries.
Why the Medical Device Directive (MDD 93/42/EEC) matters in medical device development
MDD 93/42/EEC matters today mainly as a legacy compliance context. Many devices were CE marked under the MDD, and their certificates remain the only valid basis for market access while manufacturers complete MDR conformity assessment. A lapsed certificate means a device can no longer be placed on the EU market, and Notified Body capacity constraints have made rework slower than most companies expect.
The directive also matters for due diligence. Any acquisition or supplier qualification involving an older EU-marketed device requires tracing the original MDD classification, technical file, and certificate history before assuming current market status. Getting this wrong late in a deal is expensive to fix.
How the MDD to MDR transition works
MDD 93/42/EEC built compliance around a few core mechanisms that still shape how legacy files are read today:
- Annex I essential requirements covering safety, performance, and design, the direct ancestor of MDR’s general safety and performance requirements.
- Annex IX classification rules, which sorted devices into Class I, IIa, IIb, or III based on invasiveness, duration of body contact, and energy source.
- Conformity assessment routes (Annexes II through VII) determined whether a Notified Body needed to review the quality system, the technical file, or both, depending on device class.
- Declaration of Conformity is the manufacturer’s formal statement that a device meets the applicable Annex I requirements.
The MDD was repealed when EU MDR 2017/745 became fully applicable, but Article 120 of the MDR, later amended by Regulation (EU) 2023/607, created transitional provisions for legacy devices. Class III and implantable Class IIb devices can remain on the market under a valid MDD or AIMDD certificate until December 31, 2027. Other Class IIb, Class IIa, and Class I sterile or measuring devices have until December 31, 2028. Qualifying requires no significant change in design or intended purpose, a compliant quality management system, and a written agreement with an MDR-designated Notified Body already in place. The earlier “sell-off” deadline was removed, so devices lawfully placed on the market during the transition can continue to be distributed without a separate cutoff.
Common challenges and best practices
Manufacturers often assume an MDD certificate provides open-ended market access once the extension applies. It does not: the extension only holds if the device design and intended purpose stay unchanged and the Notified Body agreement stays current. A minor design change that seems harmless from an engineering standpoint can break legacy status and force full MDR conformity assessment ahead of schedule.
Another common gap is treating the MDD-to-MDR transition as a single filing event rather than a program. Teams that start Notified Body engagement early, keep a live registry of certificate expiry dates, and run a structured gap analysis between MDD and MDR technical documentation tend to avoid last-minute scrambles. Teams that wait until close to a deadline run into Notified Body queues that stretch well beyond a year, with little room to recover from a flagged submission.
How SJML helps with the Medical Device Directive (MDD 93/42/EEC) transition
SJML’s QARA team works with manufacturers carrying legacy MDD-certified devices through the shift to EU MDR and IVDR compliance. This includes regulatory strategy and device classification review, gap analysis between existing MDD technical files and current MDR documentation requirements, DHF remediation, and ongoing regulatory sustenance for devices moving through Notified Body conformity assessment. SJML also supports M&A regulatory and quality due diligence for deals involving older EU-marketed devices, helping buyers understand what a legacy certificate does and doesn’t cover.
Frequently asked questions
No. The MDD was repealed when the EU MDR 2017/745 became fully applicable on May 26, 2021. Devices with a still-valid MDD certificate can remain on the market under transitional provisions, with deadlines of December 31, 2027, or December 31, 2028, depending on device class, provided specific conditions are met.
The EU Medical Device Regulation (MDR) 2017/745 replaced MDD 93/42/EEC, along with the Active Implantable Medical Devices Directive (AIMDD 90/385/EEC). The MDR became fully applicable on May 26, 2021, and introduced stricter clinical evidence requirements, UDI traceability, and EUDAMED registration.
Only if it qualifies as a legacy device: the certificate must still be valid, the design and intended purpose must be unchanged, the manufacturer must run a compliant quality system, and a signed agreement with an MDR-designated Notified Body must be in place by the applicable date.
Annex IX set out the classification rules that sorted devices into Class I, IIa, IIb, or III based on factors like invasiveness, duration of contact with the body, and whether the device used an energy source. This classification determined which conformity assessment route applied.
No. Any device placed on the EU market for the first time must meet EU MDR 2017/745 requirements directly. The MDD transitional provisions only apply to devices that were already CE marked under the MDD or AIMDD before May 26, 2021.
Related terms
- EU Medical Device Regulation (MDR) 2017/745
- Active Implantable Medical Devices Directive (AIMDD)
- Notified Body
- CE Marking
- Declaration of Conformity
